Fasudil Hydrochloride

DRUG6 trials

Sponsors

Helse Stavanger HF, Brigham and Women's Hospital, Colorado State University, RenJi Hospital, Technical University of Munich

Conditions

Alzheimer's diseaseCardiovascular DiseasesCarotid StenosisIdiopathic Parkinson´s DiseaseOvarian CancerST Segment Elevation Myocardial Infarction

Phase 2

Rho Kinase (ROCK) Inhibition in Carotid Atherosclerosis

TerminatedNCT00670202

Brigham and Women's HospitalCarotid Stenosis

Start: 2008-03-13End: 2011-01-20Updated: 2017-03-29

Red Blood Cell ATP Release and Vascular Function in Humans

CompletedNCT03404843

Colorado State UniversityCardiovascular Diseases

Start: 2017-07-14End: 2018-10-05Updated: 2020-02-27

Safety, Tolerability and Symptomatic Efficacy of the ROCK-Inhibitor Fasudil in Patients With Parkinson's Disease

RecruitingNCT05931575

Technical University of MunichIdiopathic Parkinson´s Disease

Start: 2023-09-11End: 2026-09-30Target: 75Updated: 2026-03-18

A PLACEBO CONTROLLED, RANDOMIZED DOUBLE-BLIND PARALLEL GROUP 12-MONTH TRIAL OF FASUDIL FOR THE TREATMENT OF EARLY ALZHEIMER’S DISEASE (FEAD)

RecruitingCTIS2023-506514-44-00

Helse Stavanger HFAlzheimer's disease

Start: 2024-06-11Target: 200Updated: 2025-10-23

A Clinical Study on Fasudil Hydrochloride for Treatment of Gene-Specific Ovarian Cancer

RecruitingNCT06890858

Zhejiang Provincial People's HospitalOvarian Cancer

Start: 2025-04-30End: 2028-01-31Target: 20Updated: 2025-03-24

Phase 4

Early Intracoronary Administration of Fasudil in the Primary PCI of ST-segment-Elevation Myocardial Infarction

RenJi HospitalST Segment Elevation Myocardial Infarction

Start: 2019-07-01End: 2022-12-30Target: 600Updated: 2018-11-26

Related Papers

Protocol for a randomized, placebo-controlled, double-blind phase IIa study of the safety, tolerability, and symptomatic efficacy of the ROCK-inhibitor Fasudil in patients with Parkinson’s disease (ROCK-PD)

Frontiers in Aging Neuroscience2024-02-1416 citations